Niacin--a case study for the role of event-driven versus surrogate endpoint trials

Heart. 2013 Nov;99(22):1631-2. doi: 10.1136/heartjnl-2013-304545. Epub 2013 Sep 16.

Authors

Michael J Blaha¹, Erin D Michos

Affiliation

¹ Department of Medicine/Cardiology, The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, , Baltimore, Maryland, USA.

PMID: 24041650
DOI: 10.1136/heartjnl-2013-304545

No abstract available

Publication types

Editorial

MeSH terms

Biomarkers
Clinical Trials as Topic / standards*
Humans
Hypolipidemic Agents / therapeutic use*
Niacin / therapeutic use*

Substances

Biomarkers
Hypolipidemic Agents
Niacin